Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration.
Development of interferon beta-neutralising antibodies in multiple sclerosis-a systematic review and meta-analysis.
Copolymer-1 promotes neurogenesis and improves functional recovery after acute ischemic stroke in rats.
Tcelna® (imilecleucel-T)
The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria.
Determination and characterization of a cannabinoid receptor in rat brain.
Efficacy and safety study of RPC1063 in relapsing multiple sclerosis patients
Development of cladribine at Scripps for hairy cell leukemia and current results.
Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease.
Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy.
Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.
Zebrafish myelination: a transparent model for remyelination?
Current and future disease-modifying therapies in multiple sclerosis.
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
Genzyme’s once-daily, oral AUBAGIO® approved in Australia for treatment of relapsing multiple sclerosis
Phase 4 GI Tolerability Study of DMF in Patients With Relapsing Forms of MS in the US (MANAGE)
Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
Withdrawal of the marketing authorization in the European Union
Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis.
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Alemtuzumab
Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis.
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.

Pages